Graphical abstract Table 1
SURPASS Clinical Trial Program The SURPASS clinical trial [5] program evaluated the efficacy and safety of tirzepatide in individuals with type 2 diabetes
In March 2026, Retatrutide met its primary endpoints in a Phase 3 diabetes trial (TRANSCEND-T2D-1), with results suggesting superior HbA1c reductions versus comparators
These figures exceed, by several-fold, the per-capita pharmaceutical budget in many health-care systems and underscore a critical, often overlooked question: not every individual with hepatic steatosis can, or should, receive high-cost pharmacotherapy
The variables most physicians miss full thyroid, hormones, ferritin, inflammation often reveal the actual bottleneck
Understand the conversion ratios between semaglutide and tirzepatide in case you need to switch medications